Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Cushing’s Syndrome in 25 Major Markets
Cushing’s syndrome is a multisystem disorder associated with chronic systemic exposure to excessive amounts of cortisol. It can be induced by both endogenous and exogenous factors and usually presents a typical set of signs and symptoms. Multiple comorbidities of Cushing’s syndrome have been identified, which significantly impact the quality of patients’ life and contribute to increased mortality.
Even though various effective treatment methods are available, including surgical, radiation-based and pharmacological interventions, recurrence of the disorder is possible. Patients in whom Cushing’s syndrome occurred during childhood can retain some physical and psychosocial disadvantage in later life.
This report provides the current prevalent population for Cushing’s syndrome across 25 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Sweden, Denmark, Finland, Bulgaria, Russia, Turkey, South Africa, Japan, China, South Korea, India, Australia, New Zealand, Brazil, Mexico) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, Cushing’s syndrome patients grouped by classification, treatments and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of Cushing’s syndrome include:
• Obesity
• Insulin resistance
• Hypertension
• Dyslipidaemia
• Hypercoagulability leading to VTE
• Osteopaenia/osteoporosis
• Psychiatric disorders (with aggravation of pre-existing tendencies)
• Impaired growth in children
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global Cushing’s syndrome market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of Cushing’s syndrome and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of Cushing’s syndrome patients.
• Identification of Cushing’s syndrome patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of Cushing’s syndrome patients.
Epiomic Epidemiology Series: Cushing’s Syndrome Forecast in 25 Major Markets 2018–2028
CONTENTS
• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE INCIDENCE FOR CUSHING’S SYNDROME
• FEATURES OF CUSHING’S SYNDROME PATIENTS
• TREATMENT OF CUSHING’S SYNDROME PATIENTS
• SURGICAL TREATMENT
• RADIOTHERAPY
• PHARMACOLOGIC TREATMENT
• COMORBIDITIES OF CUSHING’S SYNDROME PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX
LIST OF TABLES AND FIGURES
• Table 1. Classification of Cushing’s syndrome by ACTH-dependency
• Table 2. Mutations found in tumours causing Cushing’s syndrome
• Table 3. Incidence of Cushing’s syndrome, total (000s)
• Table 4. Incidence of Cushing’s syndrome, males (000s)
• Table 5. Incidence of Cushing’s syndrome, females (000s)
• Table 6. Patients with Cushing’s syndrome by classification, total (000s)
• Table 7. Patients with ACTH-dependent Cushing's syndrome by cause, total (000s)
• Table 8. Patients with Cushing's syndrome undergoing treatment, total (000s)
• Table 9. Patients with Cushing's syndrome undergoing surgical treatment, total (000s)
• Table 10. Patients with Cushing's syndrome undergoing pituitarectomy, total (000s)
• Table 11. Patients with Cushing's syndrome undergoing adrenalectomy, total (000s)
• Table 12. Patients with Cushing's syndrome undergoing radiotherapy, total (000s)
• Table 13. Patients with Cushing's syndrome undergoing pharmacologic treatment, total (000s)
• Table 14. Patients with Cushing's syndrome treated with dopamine agonists, total (000s)
• Table 15. Patients with Cushing's syndrome treated with ketoconazole, total (000s)
• Table 16. Patients with Cushing's syndrome treated with mitotane, total (000s)
• Table 17. ACTH-dependent Cushing's syndrome patients with musculoskeletal complications, total (000s)
• Table 18. ACTH-dependent Cushing's syndrome patients with cardiovascular complications, total (000s)
• Table 19. ACTH-dependent Cushing's syndrome patients with endocrine/metabolic complications, total (000s)
• Table 20. ACTH-dependent Cushing's syndrome patients with mental health complications, total (000s)
• Table 21. ACTH-dependent Cushing's syndrome patients with acne, total (000s)
• Table 22. ACTH-dependent Cushing's syndrome patients with infections, total (000s)
• Table 23. Abbreviations and acronyms used in the report
• Table 24. USA incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 25. USA incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 26. Canada incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 27. Canada incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 28. France incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 29. France incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 30. Germany incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 31. Germany incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 32. Italy incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 33. Italy incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 34. Spain incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 35. Spain incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 36. UK incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 37. UK incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 38. Poland incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 39. Poland incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 40. Netherlands incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 41. Netherlands incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 42. Norway incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 43. Norway incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 44. Sweden incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 45. Sweden incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 46. Denmark incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 47. Denmark incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 48. Finland incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 49. Finland incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 50. Bulgaria incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 51. Bulgaria incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 52. Russia incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 53. Russia incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 54. Turkey incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 55. Turkey incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 56. South Africa incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 57. South Africa incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 58. Japan incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 59. Japan incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 60. China incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 61. China incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 62. South Korea incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 63. South Korea incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 64. India incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 65. India incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 66. Australia incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 67. Australia incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 68. New Zealand incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 69. New Zealand incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 70. Brazil incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 71. Brazil incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
• Table 72. Mexico incidence of Cushing’s syndrome by 5-yr age cohort, males (000s)
• Table 73. Mexico incidence of Cushing’s syndrome by 5-yr age cohort, females (000s)
